Jacob E. Berchuck, MD
-
RoleMedical Oncology
-
Research Program
-
Practicing Since2020
Background
Jacob Berchuck, MD, is a board-certified medical oncologist specializing in the treatment of genitourinary cancers. Dr. Berchuck is an attending physician at Winship Cancer Institute of Emory University and an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Before joining Emory in 2024, Dr. Berchuck was an assistant professor of medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute.
Dr. Berchuck earned his MD from Duke University in Durham, North Carolina. He completed his residency in internal medicine at the University of California, San Francisco, and his fellowship in medical oncology, along with a postdoctoral research fellowship, at Dana-Farber Cancer Institute/Harvard Medical School.
Titles & Roles
-
Assistant Professor, Department of Hematology and Medical OncologyEmory University School of Medicine
Education & Training
Education
- Fellowship, Hematology/Oncology, 2020Dana-Farber Cancer Institute
- Gap in Credential/List explanation in comments, 2017GAP in Education. List details in comments
- Residency, Internal Medicine, 2016UCSF School of Medicine
- Internship, Internal Medicine, 2014UCSF School of Medicine
- Medical Education, MD, 2013Duke University School of Medicine
Board Certifications
- Medical OncologyAmerican Board of Internal Medicine, 2020Internal MedicineAmerican Board of Internal Medicine, 2016
Professional Memberships
- American Society of Clinical Oncology
- American Association of Cancer Research
Research
Dr. Berchuck’s research focuses on developing biomarkers to guide treatment decisions, deciphering mechanisms of treatment resistance and discovering novel therapeutic strategies. His research utilizes “liquid biopsies” — studying tumor biology by profiling cell-free DNA circulating in the bloodstream — aiming for a future where a simple blood draw can provide real-time insights to choose the right treatment for the right patient at the right time.
Publications
Dr. Berchuck’s research has been published in several leading journals, including Nature Medicine, Cancer Cell, Annals of Oncology, JAMA Oncology, European Urology, and Clinical Cancer Research.
Title/Journal Authors Publication Date The Prostate
D Boiarsky, AK Tewari, DC Gulhan, Z Bakouny, G Ananda, H Savignano, G Lakshminarayanan, HM McClure, R Silver, TK Choueiri, ME Taplin, PJ Park, JE Berchuck 12/01/2024 Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
Clinical cancer research : an official journal of the American Association for Cancer Research
R Nawfal, R El Hajj Chehade, JE Berchuck 11/04/2024 Insulin resistance during androgen deprivation therapy in men with prostate cancer.
Cancer
S Basaria, ME Taplin, M McDonnell, DC Simonson, AP Lin, AB Dufour, D Habtemariam, PL Nguyen, P Ravi, AS Kibel, CJ Sweeney, AV D'Amico, DA Roberts, W Xu, XX Wei, R Sunkara, AD Choudhury, C Mantia, H Beltran, M Pomerantz, JE Berchuck, NE Martin, JE Leeman, KW Mouw, KE Kilbridge, R Bearup, H Kackley, H Kafel, G Huang, KF Reid, T Storer, M Braga-Basaria, TG Travison 11/01/2024 Clinical cancer research : an official journal of the American Association for Cancer Research
KH Stopsack, J Vijai, M Conry, JE Berchuck, Y Kemel, SE Vasselman, DA Freeman, GM Lee, D Mandelker, DB Solit, MJ Morris, KL Penney, W Abida, K Offit, LA Mucci, PW Kantoff, MM Pomerantz 10/25/2024 Clinical cancer research : an official journal of the American Association for Cancer Research
T El Zarif, CB Meador, X Qiu, JH Seo, MP Davidsohn, H Savignano, G Lakshminarayanan, HM McClure, J Canniff, B Fortunato, R Li, MK Banwait, K Semaan, M Eid, H Long, YP Hung, NR Mahadevan, DA Barbie, MG Oser, Z Piotrowska, TK Choueiri, SC Baca, AN Hata, ML Freedman, JE Berchuck 09/03/2024 Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.